Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery and development of its proprietary Anticalin® class of biotherapeutics. The company has successfully developed a clinical-stage pipeline and closed commercial collaboration with firms like Daiichi Sankyo, Sanofi Pasteur and Allergan.
Pieris Pharmaceuticals began trading on the OTC Markets on December 18, 2014 and later at NASDAQ (Nasdaq: PIRS) on June 30, 2015.
Pieris is located in Boston and in the Munich area (Germany).